Filip Goossens
Senior Business and Investment Manager
Get their honest, personalized take on your startup.
Sign in to pitch Filip →At a glance
- Full Name
- Filip Goossens
- Firm
- Sopartec
- Firm Type
- University technology-transfer and investment company affiliated with UCLouvain; connected to VIVES early-stage investment funds
- Investment Stage
- Early-stage to Series A; VIVES also describes its remit as seed, start-up, and growth
- Check Size
- €100,000 to €7,000,000 per investment line through VIVES
- Target Company Profile
- Young high-tech companies with strong intellectual property, breakthrough technology, positive societal impact, economic business-model relevance, a large potential market, and multidisciplinary experienced teams
- Sector Focus
- Multisector technology, with main verticals in life sciences, ag tech, and hard engineering
- Geographic Focus
- Europe, excluding Switzerland and the UK; preference for Belgium and neighboring countries
- Location
- Louvain-la-Neuve, Belgium
Background
I could not verify a current public Sopartec or VIVES team profile for Filip Goossens. The current Sopartec team page lists Xavier Bastin, Benoît Limage, Alexandra Safiannikoff, Michèle Hody, Damien Bertrand, Mélanie Lecomte, Philippe Peltier, and Sasha Sekulic, but does not list Filip Goossens. The current VIVES team page also does not list him.
Sopartec is the technology-transfer and investment company of the Université catholique de Louvain. Within the Louvain Technology Transfer Office, Sopartec’s mission is to valorize research from UCLouvain, Cliniques universitaires St-Luc, CHU UCL Namur, and the de Duve Institute through spin-off creation and license agreements.
Sopartec works with the VIVES investment funds. VIVES was initiated by UCLouvain and is managed by VIVES Partners; it invests in disruptive, high-technology companies with positive societal impact. VIVES I was created in 2004, VIVES II closed a first round in 2011 at €43 million, and VIVES Inter University Fund was created in summer 2020 with €75 million.
Investment Thesis & Focus
- VIVES states that its strategy is “to invest in young high-tech companies” that bring a unique solution to market demand through “breakthrough” technology.
- The fund invests from €100,000 to €7,000,000 per investment line.
- Investment criteria include strong intellectual property, positive societal impact, a link to one of VIVES’s university or incubator partners as a plus, and a geographically European head office.
- Sector scope is generalist technology, with three main verticals: life sciences, ag tech, and hard engineering.
- VIVES evaluates companies from early stage to Series A and says it can invest at seed, start-up, and growth stages.
- The fund looks for economic relevance in the business model, a large potential market, a multidisciplinary experienced team, aligned long-term shareholders, and an expected average investment period of about seven years with trade-sale or IPO exit prospects.
- VIVES may invest alongside other investors and may act as lead investor coordinating syndicated transactions.
Notable Investments
- Syndesi Therapeutics — Pharma company developing SV2A modulators for Alzheimer’s disease and cognitive impairment; VIVES lists a 2018 investment and 2022 exit.
- iTeos Therapeutics — Cancer immunotherapy company based on Ludwig Cancer Research and de Duve Institute/UCLouvain work; VIVES lists a 2013 investment and 2025 exit.
- e-Peas — Engineering company developing energy-harvesting and ultra-low-power semiconductor products for IoT devices; VIVES lists a 2017 investment.
- Sunrise — MedTech company developing Sensa, a wearable sleep-apnea diagnostic device; VIVES lists a 2021 investment.
- Generare — Paris-based techbio company generating novel molecular data for drug discovery; announced a €20 million Series A in April 2026 with VIVES Partners participating.
- Bionyra Pharma — Clinical-stage biopharma developing next-generation biologics for immune-mediated inflammatory diseases; launched in June 2026 with a $165 million Series A including VIVES Partners participation.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.